Some health startups want to treat disease. Sensifai Health wants to ambush it before it ever shows up at the party.
Fresh out of stealth and straight out of the Research Institute of the McGill University Health Centre (RI-MUHC), this Canadian-Israeli preemptive health company just secured an undisclosed seed round led by Glen Ventures, with firepower from Eurêka Investment Fund. But the real story isn’t the funding, it’s the fuse they just lit under an industry still busy playing catch-up.
Dr. Amir Hadid, Sensifai’s co-founder and CEO, isn’t building another digital symptom checker for hypochondriacs. This is a guy who’s done time in labs, lecture halls, and boardrooms. From BD to LifeBond, from McGill postdoc to entrepreneur, Hadid brings scientific rigor and real-world grit. Backing him are clinical heavyweights like Dr. Dennis Jensen, now Chief Scientific Officer and a Canada Research Chair, and Dr. Emily McDonald, Sensifai’s CMO and the force behind MedSafer. When your leadership reads like a who’s who of translational medicine, you’re not here to pitch ideas, you’re here to change the game.
And the platform? Certified heat. Sensifai takes off-the-shelf wearables, Apple Watch, Fitbit, Oura Ring, and runs 2 billion biometric data points through their proprietary AI. The result: a system that predicts acute inflammation before symptoms appear. Not hypothetically. Clinically validated. Peer-reviewed. Published in The Lancet Digital Health. And unlike most “innovation,” this thing doesn’t require a new device or a new behavior, just new thinking.
Their initial target? COPD, the world’s third leading cause of death and a $195 billion problem. Sensifai’s early detection could reduce hospitalizations by half. If that stat doesn’t make payers, pharma, and digital health platforms perk up, they’re either asleep or bankrupt.
Glen Ventures, founded by Samuel Ohayon and Michael Goodman, knew what they were doing when they led the round. With ties to the McGill ecosystem and a mandate from Eurêka to find Quebec’s healthtech gems, they didn’t just invest, they made a statement. This isn’t about “what if.” It’s about “what’s next.”
Sensifai’s model? B2B, global, and ready to scale. They’re not chasing vanity metrics. They’re turning passive data into proactive medicine, early alerts, zero extra hardware, and full compatibility with the devices patients already wear. And with former US Assistant Secretary for Health Dr. Brett Giroir now in the fold as a strategic partner, the only thing more inevitable than Sensifai’s expansion is the industry’s reaction when they realize they’ve been scooped by science and a smarter playbook.
This isn’t prevention. It’s precision ambush. And if you’re in healthcare and still reacting to flare-ups, Sensifai just made you look like the last kid to show up with a flip phone.
Let’s call it what it is: the moment preemptive health stopped being theory and started throwing punches.
